AKRO PE Ratio & Valuation,Is AKRO Overvalued

AKRO Relative Valuation

AKRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AKRO is overvalued; if below, it's undervalued.

Historical Valuation

Akero Therapeutics Inc (AKRO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.01. The fair price of Akero Therapeutics Inc (AKRO) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：54.67

Fair

-13.35

-9.72

EV/EBITDA

Akero Therapeutics Inc. (AKRO) has a current EV/EBITDA of -9.72. The 5-year average EV/EBITDA is -6.29. The thresholds are as follows: Strongly Undervalued below -13.78, Undervalued between -13.78 and -10.03, Fairly Valued between -2.54 and -10.03, Overvalued between -2.54 and 1.20, and Strongly Overvalued above 1.20. The current Forward EV/EBITDA of -9.72 falls within the Historic Trend Line -Fairly Valued range.

-9.33

EV/EBIT

Akero Therapeutics Inc. (AKRO) has a current EV/EBIT of -9.33. The 5-year average EV/EBIT is -6.25. The thresholds are as follows: Strongly Undervalued below -13.72, Undervalued between -13.72 and -9.99, Fairly Valued between -2.51 and -9.99, Overvalued between -2.51 and 1.22, and Strongly Overvalued above 1.22. The current Forward EV/EBIT of -9.33 falls within the Historic Trend Line -Fairly Valued range.

0.00

Akero Therapeutics Inc. (AKRO) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-15.45

P/OCF

Akero Therapeutics Inc. (AKRO) has a current P/OCF of -15.45. The 5-year average P/OCF is -11.19. The thresholds are as follows: Strongly Undervalued below -20.87, Undervalued between -20.87 and -16.03, Fairly Valued between -6.35 and -16.03, Overvalued between -6.35 and -1.51, and Strongly Overvalued above -1.51. The current Forward P/OCF of -15.45 falls within the Historic Trend Line -Fairly Valued range.

-15.45

P/FCF

Akero Therapeutics Inc. (AKRO) has a current P/FCF of -15.45. The 5-year average P/FCF is -11.67. The thresholds are as follows: Strongly Undervalued below -24.57, Undervalued between -24.57 and -18.12, Fairly Valued between -5.22 and -18.12, Overvalued between -5.22 and 1.22, and Strongly Overvalued above 1.22. The current Forward P/FCF of -15.45 falls within the Historic Trend Line -Fairly Valued range.

Akero Therapeutics Inc (AKRO) has a current Price-to-Book (P/B) ratio of 4.57. Compared to its 3-year average P/B ratio of 3.73 , the current P/B ratio is approximately 22.77% higher. Relative to its 5-year average P/B ratio of 3.77, the current P/B ratio is about 21.20% higher. Akero Therapeutics Inc (AKRO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -7.83%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -9.38% , the current FCF yield is about -100.00% lower.

4.57

P/B

Median3y

3.73

Median5y

3.77

-5.57

FCF Yield

Median3y

-7.83

Median5y

-9.38

Competitors Valuation Multiple

The average P/S ratio for AKRO's competitors is 25.07, providing a benchmark for relative valuation. Akero Therapeutics Inc Corp (AKRO) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of AKRO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of AKRO in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Akero Therapeutics Inc (AKRO) currently overvalued or undervalued?

What is Akero Therapeutics Inc (AKRO) fair value?

AKRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Akero Therapeutics Inc (AKRO) is between to according to relative valuation methord.

How does AKRO's valuation metrics compare to the industry average?

The average P/S ratio for AKRO's competitors is 25.07, providing a benchmark for relative valuation. Akero Therapeutics Inc Corp (AKRO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Akero Therapeutics Inc (AKRO) as of Dec 15 2025?

As of Dec 15 2025, Akero Therapeutics Inc (AKRO) has a P/B ratio of 4.57. This indicates that the market values AKRO at 4.57 times its book value.

What is the current FCF Yield for Akero Therapeutics Inc (AKRO) as of Dec 15 2025?

As of Dec 15 2025, Akero Therapeutics Inc (AKRO) has a FCF Yield of 0.00%. This means that for every dollar of Akero Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Akero Therapeutics Inc (AKRO) as of Dec 15 2025?

As of Dec 15 2025, Akero Therapeutics Inc (AKRO) has a Forward P/E ratio of -13.35. This means the market is willing to pay $-13.35 for every dollar of Akero Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Akero Therapeutics Inc (AKRO) as of Dec 15 2025?

As of Dec 15 2025, Akero Therapeutics Inc (AKRO) has a Forward P/S ratio of 0.00. This means the market is valuing AKRO at $0.00 for every dollar of expected revenue over the next 12 months.

AKRO Valuation